Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1

Molecular Cancer Therapeutics

Volumn 10, Issue 7, 2011, Pages 1264-1275

  Zhang, Chong ^a   Cai, Tian Yu ^a   Zhu, Hong ^a   Yang, Liu Qing ^a   Jiang, Hai ^b   Dong, Xiao Wu ^a   Hu, Yong Zhou ^a   Lin, Neng Ming ^c   He, Qiao Jun ^a   Yang, Bo ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CASPASE 3; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; SMALL INTERFERING RNA; UBIQUITIN; UBIQUITIN SPECICFIC PROTEASE 9; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; ENZYME ACTIVATION; GENE SILENCING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; LUNG CANCER; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TREATMENT DURATION; TUMOR CELL; TUMOR VOLUME; UBIQUITINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BIPHENYL COMPOUNDS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG SYNERGISM; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, NUDE; NEOPLASMS; NITROPHENOLS; PIPERAZINES; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; SULFONAMIDES; UBIQUITIN THIOLESTERASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960146856     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-1091     Document Type: Article

References (49)

1. Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst 2008;100:580-95.
2. Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007;67:782-91. (Pubitemid 46192219)
3. Zhong Q, Gao W, Du F, Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005;121:1085-95. (Pubitemid 40884398)
4. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010;463:103-7.
5. Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005;123:773-86. (Pubitemid 41721026)
6. Ovaa H, Kessler BM, Rolen U, Galardy PJ, Ploegh HL, Masucci MG. Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells. Proc Natl Acad Sci U S A 2004;101:2253-8. (Pubitemid 38269298)
7. Nagai H, Noguchi T, Homma K, Katagiri K, Takeda K, Matsuzawa A, et al. Ubiquitin-like sequence in ASK1 plays critical roles in the recognition and stabilization by USP9X and oxidative stress-induced cell death. Mol Cell 2009;36:805-18.
8. Dupont S, Mamidi A, Cordenonsi M, Montagner M, Zacchigna L, Adorno M, et al. FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell 2009; 136:123-35.
9. Mouchantaf R, Azakir BA, McPherson PS, Millard SM, Wood SA, Angers A. The ubiquitin ligase itch is auto-ubiquitylated in vivo and in vitro but is protected from degradation by interacting with the deubiquitylating enzyme FAM/USP9X. J Biol Chem 2006;281: 38738-47. (Pubitemid 46042001)
10. Jolly LA, Taylor V, Wood SA. USP9X enhances the polarity and self-renewal of embryonic stem cell-derived neural progenitors. Mol Biol Cell 2009;20:2015-29.
11. Hussain SA, Palmer DH, Swinson DE, Riley P, Wills A, Brown C, et al. A phase II clinical trial of gemcitabine and split dose cisplatin in advanced non-small cell lung cancer in an outpatient setting. Oncol Rep 2008;20:233-7.
12. Michael M, Moore M. Clinical experience with gemcitabine in pancreatic carcinoma. Oncology 1997;11:1615-22. (Pubitemid 27505663)
13. Cohen MH, Rothmann M. Gemcitabine and cisplatin for advanced, metastatic bladder cancer. J Clin Oncol 2001;19:1229-31. (Pubitemid 32176302)
14. Airoldi M, Cattel L, Passera R, Pedani F, Delprino L, Micari C. Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data. Am J Clin Oncol 2006;29:490-4. (Pubitemid 44536032)
15. Bergman AM, Eijk PP, Ruiz van Haperen VW, Smid K, Veerman G, Hubeek I, et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 2005;65:9510-6.
16. Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study-The UK ABC-01 Study. Br J Cancer 2009;101:621-7.
17. Benekli M, Yildiz R, Uner A, Er O, Yamac D, Alkis N, et al. Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Oncology 2007;72:308-13. (Pubitemid 351238142)
18. Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R, et al. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res 2009;15:5584-90.
19. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-81. (Pubitemid 40825512)
20. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10: 375-88. (Pubitemid 44693472)
21. Kojima K, Konopleva M, Samudio IJ, Schober WD, Bornmann WG, Andreeff M. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. Cell Cycle 2006;5:2778-86. (Pubitemid 44901740)
22. Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P, et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007;26:2374-80.
23. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10:389-99. (Pubitemid 44711953)
24. Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010;115:3304-13.
25. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007;117:112-21. (Pubitemid 46048458)
26. Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, et al. Influence of Bcl-2 familymembersonthe cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007;67:1176-83.
27. Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Mol Pharmacol 2009;75:1231-9.
28. Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned TM, et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 2007;110:2057-66.
29. Wesarg E, Hoffarth S, Wiewrodt R, Kröll M, Biesterfeld S, Huber C, et al. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer 2007;121:2387-94. (Pubitemid 350022407)
30. Hauck P, Chao BH, Litz J, Krystal GW. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Mol Cancer Ther 2009;8:883-92.
31. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA, et al. "Seed" analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 2007;26:3972-9.
32. Zhu H, Ding WJ, Wu R, Weng QJ, Lou JS, Jin RJ, et al. Synergistic anti-cancer activity by the combination of TRAIL/APO-2L and celastrol. Cancer Invest 2010;28:23-32.
33. Luo P, He Q, He X, Hu Y, Lu W, Cheng Y, et al. Potent antitumor activity of 10-methoxy-9-nitrocamptothecin. Mol Cancer Ther 2006;5:962-8. (Pubitemid 43724596)
34. Chou TC TP. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:29.
35. Chou TC TP. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 1981;115:10.
36. Huang S, Sinicrope FA. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res 2008;68:2944-51. (Pubitemid 351556295)
37. Marriott HM, Bingle CD, Read RC, Braley KE, Kroemer G, Hellewell PG, et al. Dynamic changes in Mcl-1 expression regulate macrophage viability or commitment to apoptosis during bacterial clearance. J Clin Invest 2005;115:359-68. (Pubitemid 40385477)
38. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 2006;21:749-60. (Pubitemid 43376126)
39. Bhat UG, Pandit B, Gartel AL. ARC synergizes with ABT-737 to induce apoptosis in human cancer cells. Mol Cancer Ther 2010;9:1688-96.
40. Csoka K, Liliemark J, Larsson R, Nygren P. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol 1995;22:47-53.
41. Hensley ML, Larkin J, Fury M, Gerst S, Tai DF, Sabbatini P, et al. A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer. Clin Cancer Res 2008;14:6310-6.
42. van Moorsel CJ, Veerman G, Ruiz van Haperen VW, Bergman AM, Jensen PB, Sehested M, et al. Differential effects of gemcitabine on nucleotide pools of 19 solid tumor cell lines. Adv Exp Med Biol 1998;431:661-5. (Pubitemid 28236856)
43. Bergman AM, Kuiper CM, Noordhuis P, Smid K, Voorn DA, Comijn EM, et al. Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and in human xenografts. Nucleosides Nucleotides Nucleic Acids 2004;23:1329-33. (Pubitemid 39625919)
44. Kim KW, Moretti L, Mitchell LR, Jung DK, Lu B. Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radio-sensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model. Clin Cancer Res 2009;15:6096-105.
45. Deng Y, Wu X. Peg3/Pw1 promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria. Proc Natl Acad Sci U S A 2000;97:12050-5.
46. Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, et al. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res 2007;13:7191-8. (Pubitemid 350276906)
47. Cory S, Adams JM. Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell 2005;8:5-6. (Pubitemid 40991809)
48. Thomson DM, Hansen MD, Winder WW. Regulation of the AMPK-related protein kinases by ubiquitination. Biochem J 2008;411:e9-10.
49. Marx C, Held JM, Gibson BW, Benz CC. ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination. Cancer Res 2010;70:3709-17.